Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

IgD subtype but not IgM or non-secretory is a prognostic marker for poor survival following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results from the EBMT CALM (Collaboration to collect Autologous Transplant Outcomes in Lymphomas and Myeloma) study

Lawless, Sarah, Sbianchi, Giulia, Morris, Curly, Iacobelli, Simona, Bosman, Paul, Blaise, Didier, Reményi, Péter, Byrne, J.L., Mayer, Jiri, Apperley, Jane, Lund, Johan, Kobbe, Guido, Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Basak, Grzegorz, Touzeau, Cyrille, Wilson, Keith M.O., González Muñiz, Soledad, Scheid, Christof, Browne, Paul, Anagnostopoulos, Achilles, Rambaldi, Alessandro, Jantunen, Esa, Kröger, Nicolaus, Schönland, Stefan, Yakoub-Agha, Ibrahim and Garderet, Laurent 2021. IgD subtype but not IgM or non-secretory is a prognostic marker for poor survival following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results from the EBMT CALM (Collaboration to collect Autologous Transplant Outcomes in Lymphomas and Myeloma) study. Clinical Lymphoma, Myeloma and Leukemia 21 (10) , pp. 686-693. 10.1016/j.clml.2021.05.012

Full text not available from this repository.

Abstract

Background The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data. Patients This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with “usual” and “rare” myelomas. Results Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis. Conclusion We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Elsevier
ISSN: 2152-2650
Date of Acceptance: 16 May 2021
Last Modified: 14 Mar 2022 10:30
URI: https://orca.cardiff.ac.uk/id/eprint/148092

Actions (repository staff only)

Edit Item Edit Item